ERT hires Linda Deal

To head its Health Outcomes Research initiatives

ERT, a US headquartered provider of clinical services and customisable medical devices, has appointed Linda Deal to lead its Health Outcomes Research initiatives.

Most recently Deal was the Immunology Patient Reported Outcomes (PRO) lead at Janssen Pharma, a division of Johnson & Johnson. Prior to this, she headed the PRO Centre in Global Health Outcomes Assessment (GHOA) at Wyeth Research, now part of Pfizer. She has also supported health economics and outcomes research for Wyeth, Research Triangle Institute, and Glaxo Welcome.

In the context of health outcomes research ERT’s ePRO solutions are said to offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods.

The ePRO suite comprises an IVR solution (VIAPhone), a digital pen (VIAPen), a handheld device (VIAPad) and an Internet application (VIAWeb).

You may also like

Regulatory

ERT introduces solution to measure Lung Clearance Index

Solution provides greater data granularity to measure disease progression in respiratory trials where standard spirometry is insufficient
Regulatory

ERT recognised for improving and accelerating clinical research

Company named finalist for PACT Technology Company of the Year Award
Regulatory

Exco InTouch launches Gather and redefines the use of mobile technology in clinical trials

New product suite supports patients, sites and sponsors throughout the clinical journey
Regulatory

Scottish Equity Partners takes minority stake in Exco InTouch

Will provide a initial investment of £3m to accelerate mobile patient communication solutions
Regulatory

Almac and Exco InTouch form alliance

To deliver patient compliance as well as ePRO services using multiple technologies
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Regulatory

Crown Bioscience achieves second CLIA certification of 2025 at Suzhou Laboratory

Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability and quality
Subscribe now